Get the Stockscreener App
68.35
1.49%
0.96
Dexcom Inc stock is traded at $68.35, with a volume of 1.64M.
It is up +1.49% in the last 24 hours and down -3.25% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$67.39
Open:
$67.4
24h Volume:
1.64M
Relative Volume:
0.41
Market Cap:
$27.22B
Revenue:
$4.03B
Net Income/Loss:
$576.20M
P/E Ratio:
47.80
EPS:
1.43
Net Cash Flow:
$630.70M
1W Performance:
+12.70%
1M Performance:
-3.25%
6M Performance:
+1.93%
1Y Performance:
-49.17%
1-Day Range:
$66.98
$68.50
1-Week Range:
$59.62
$73.50
52-Week Range:
$57.52
$139.24
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
68.33 | 27.22B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
126.00 | 220.60B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
94.08 | 140.08B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.84 | 134.40B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.88 | 107.53B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.65 | 41.23B | 5.72B | 4.17B | 259.90M | 6.97 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - MarketScreener
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What Does the Market Think About DexCom? - benzinga.com
What to Expect From DexCom's Next Quarterly Earnings Report - TradingView
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - benzinga.com
Stifel maintains DexCom stock Buy rating, $100 target post FDA nod - Investing.com Australia
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barron's
Dexcom wins FDA nod for 15-day CGM - MassDevice
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - ACCESS Newswire
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction - The Motley Fool
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday - benzinga.com
DexCom (DXCM) Receives FDA Clearance for Enhanced Glucose Monito - GuruFocus
DexCom Says G7 15 Day Continuous Glucose Monitoring System Gets US FDA Clearance - MarketScreener
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wea - GuruFocus
Dexcom stock rises on FDA nod for new CGM (DXCM:NASDAQ) - Seeking Alpha
FDA OKs Dexcom G7 15-Day Continuous Glucose Monitor - Medical Product Outsourcing
DexCom shares rise on FDA clearance for new CGM system - Investing.com Australia
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom
Mizuho Initiates Coverage of DexCom (DXCM) with Outperform Recommendation - Nasdaq
What 6 Analyst Ratings Have To Say About DexCom - benzinga.com
Mizuho Initiates DexCom at Outperform With $85 Price Target - MarketScreener
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Medical Professionals Reference
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM STOCK ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - Yahoo Finance
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - ACCESS Newswire
DexCom (NasdaqGS:DXCM) Down 12% As Jon Coleman Becomes Chief Commercial Officer - Yahoo Finance
Citigroup Adjusts DexCom Price Target to $80 From $104, Maintains Buy Rating - MarketScreener
DXCM INVESTIGATION UPDATE: DexCom, Inc. Investors with Losses on their Investment are Notified of Securities Fraud Investigation; Contact BFA Law for Details (Nasdaq:DXCM) - ACCESS Newswire
DXCM INVESTOR UPDATE: Suffer Losses on Your DexCom, Inc. Investment? Contact BFA Law by October 21 about Pending Class Action Lawsuit (Nasdaq:DXCM) - FinTech Futures
ATTENTION DexCom, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
DexCom, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
DXCM INVESTOR ALERT: DexCom, Inc. Investors are Notified to Contact BFA Law before October 21 Deadline in Class Action Lawsuit - ACCESS Newswire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
Why We're Not Concerned Yet About DexCom, Inc.'s (NASDAQ:DXCM) 25% Share Price Plunge - simplywall.st
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit – DXCM - ACCESS Newswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):